| Original language | English |
|---|
| Article number | e1218 |
|---|
| Pages (from-to) | 1-8 |
|---|
| Number of pages | 8 |
|---|
| Journal | MicrobiologyOpen |
|---|
| Volume | 10 |
|---|
| Issue number | 4 |
|---|
| DOIs | |
|---|
| Published | Aug 2021 |
|---|
| Additional links | |
|---|
Funding Information:
We thank HEC Pakistan for supporting AH's doctoral placement at King's College London. We acknowledge funding from PHE Pipeline (project 109502) and grant‐in‐aid projects (Project 109505 and 111742) for this work. We also thank Ginny Moore of Public Health England for providing strains isolated from UK hospitals. C. auris
Funding Information:
We thank HEC Pakistan for supporting AH's doctoral placement at King's College London. We acknowledge funding from PHE Pipeline (project 109502) and grant-in-aid projects (Project 109505 and 111742) for this work. We also thank Ginny Moore of Public Health England for providing C.?auris strains isolated from UK hospitals.
Publisher Copyright:
© 2021 The Authors. Microbiology Open published by John Wiley & Sons Ltd.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
mbo3.1218
mbo3.1218.pdf, 695 KB, application/pdf
Uploaded date:12 Aug 2021
Version:Final published version
Licence:CC BY
Invasive Candida infections in hospitalized and immunocompromised or critically ill patients have become an important cause of morbidity and mortality. There are increasing reports of multidrug resistance in several Candida species that cause Candidemia, including C. glabrata and C. auris, with limited numbers of antifungal agents available to treat patients with invasive Candida infections. Therefore, there is an urgent need to discover new antifungal agents that work against multidrug-resistant Candida species, particularly C. auris, which has been identified as an emerging global pathogen. In this article, we report a new class of antifungal agents, the Schiff bases of sulphonamides, that show activity against all Candida species tested, with an MIC range of 4–32 µg/ml. Compound 2b showed activity against C. glabrata and a panel of fluconazole-resistant C. auris strains, with MICs of 4–16 µg/ml. The drug-like nature of these Schiff bases offers opportunities to optimize these compounds with medicinal chemistry techniques to obtain more potent analogs that can be progressed toward pre-clinical evaluation.